Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Johnson K, Brooks B, Ford C, Goodman A, Guarnaccia J, Lisak R, Myers L, Panitch H, Pruitt A, Rose J, Kachuck N, Wolinsky J. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis Journal 2000, 6: 255-266. PMID: 10962546, DOI: 10.1177/135245850000600407.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdultCohort StudiesDisabled PersonsDouble-Blind MethodFemaleGlatiramer AcetateHumansMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingNervous SystemPatient DropoutsPeptidesTime FactorsConceptsExpanded Disability Status ScaleOpen-label phaseOpen-label studyAccumulation of disabilityDaily subcutaneous injectionsGlatiramer acetateRelapse rateMultiple sclerosisSubcutaneous injectionRelapsing-remitting multiple sclerosisMean annual relapse rateDouble-blind cohortDouble-blind phaseSustained clinical benefitDouble-blind studyDisability Status ScaleAnnual relapse rateMultiple sclerosis patientsSclerosis patientsClinical benefitStatus ScaleSustained efficacyPatientsActive drugGlatiramer